English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We read with great interest the comments from D. Cattaneo and co-workers on our article describing a retrospective study in multidrug-resistant tuberculosis (MDR-TB) patients receiving linezolid tailored to the individual patient using therapeutic drug monitoring as part of their regular treatment [1]. Cattaneo and co-workers correctly summarise that one of our findings was that we did not observe any significant differences between exposure to linezolid and adverse events. Indeed, this observation may be surprising with a toxic drug like linezolid, but it is not a reason to rule out therapeutic drug monitoring as a tool for optimising the treatment regimens of TB patients. The explanation for this lies in the design of our study, the characteristics of the patient population, and the specific dosing regimen used for MDR-TB patients

Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?